Insights on the removal of the azole pesticides included in the EU Watch List by Catalytic Wet Peroxide Oxidation

The aim of this work is to evaluate the feasibility of the Catalytic Wet Peroxide Oxidation (CWPO) process using the inexpensive and environmentally friendly Fe3O4-R400 catalyst for the removal from water of a representative group of azole pesticides recently listed in the European Union (EU) Watch Lists (penconazole (PEN), prochloraz (PCZ), tebuconazole (TEB), tetraconazole (TET), metconazole (MET)). The complete removal of these pollutants (1000 μg L−1) was achieved in <1 h reaction time under ambient conditions using a catalyst concentration of 0.5 g L−1 and the stoichiometric dose of H2O2 (3 – 5 mg L−1) at a slightly acidic pH (pH0 = 5.0). To further demonstrate the effectiveness of the process, the ecotoxicity abatement was also considered. The initial toxicity of the pesticides and the CWPO effluents were evaluated with the brine shrimp Artemia salina and the bacterium Vibrio fischeri. Remarkably, the effluents were non-toxic for V. fischeri and a decrease of more than 80% in mortality was achieved for A. salina. Furthermore, the versatility of the system was proved in real water matrices (surface water and WWTP effluent), although a slight decrease on the oxidation rate was found due to the occurrence of organic matter and inorganic salts. The reactivity of the azole pesticides was finally compared with the achieved for other groups of pollutants included in the EU Watch Lists (pharmaceuticals, hormones, and neonicotinoid pesticides). Clearly, azole compounds showed the least reactivity to oxidation, suggesting that they can be used as general indicators of the overall efficiency of the proposed catalytic system for the removal of EU Watch Lists micropollutantsThis research has been supported by the Spanish AEI through the project PID2019-105079RB-100 and by the CM, Spain through the project P2018/EMT-4341. M. Munoz, N. Lopez-Arago and J. Nieto-Sandoval thanks the Spanish AEI for the Ramón y Cajal postdoctoral contract (RYC-2016-20648), the FPI predoctoral, Spain grant (PRE2020-09452) and the FPI postdoctoral, Spain grant (BES-2017-081346), respectivel

Application of catalytic hydrodechlorination for the fast removal of chlorinated azole pesticides in drinking water

Catalytic hydrodechlorination (HDC) is regarded as a promising purifying technology for drinking water treatment. So far, it has proved to be highly effective for the removal of different groups of chlorinated micropollutants including pharmaceuticals, neonicotinoid pesticides, personal care products or chloroacetic acids. The azole pesticides, recently included in the EU Watch Lists (Decisions 2020/1161 and 2022/1307), are a group of micropollutants of particular concern for drinking water given their high toxicity, persistence, and bioaccumulation potential. In this work, the feasibility of HDC for the removal of a representative group of chlorinated azole pesticides tebuconazole (TEB), tetraconazole (TET), prochloraz (PCZ), penconazole (PEN), metconazole (MET) and imazalil (IMZ)) is demonstrated, and their reactivity is compared with that observed for other halogenated micropollutant groups. Notably, all the pesticides investigated in this work (100 μg L− 1 ) were completely dechlorinated within 30 min under ambient conditions using a 1 wt% Pd/Al2O3 catalyst concentration of 0.25 g L− 1 and a H2 feeding of 50 mL N min− 1 . The experimental data were accurately described by a pseudo-first order kinetic equation and rate constant values in the range from 1.08 to 2.60 L gcat − 1 min− 1 were obtained. These values are quite close to those achieved for the most reactive neonicotinoid pesticides and significantly higher than the obtained for chloroacetic acids and most pharmaceuticals (e.g. diclofenac, sertraline or chlorpromazine). From the identification of the generated reaction intermediates and the final nonchlorinated products, sequential reaction pathways were proposed for each pollutant. Remarkably, despite the high toxicity exhibited by the azole pesticides tested, with LC50 values within the 0.4–7.0 mg L− 1 range using A. salina, HDC effluents were non-toxic in all cases. Furthermore, the catalyst showed a remarkable stability upon three consecutive runs. Finally, the versatility of the process was demonstrated in the treatment of real aqueous matrices such as DWTP and tap water, where no significant differences were found either in terms of activity or stabilityThis research has been supported by the Spanish MINECO through project PID2019-105079RB-I00 and by the CM through project P2018/ EMT-4341. J. Nieto-Sandoval and M. Munoz thanks the MINECO for the FPI contract (BES-2017-081346) and the Ramon ´ y Cajal postdoctoral contract (RYC-2016-20648), respectively. R. B. del Olmo thanks the Operational Program for Youth Employment and the Youth Employment Initiative (YEI) of the CM for his contract as Research Assistant (PEJ2020-AI/AMB-19161

Detailed stratified GWAS analysis for severe COVID-19 in four European populations

Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our understanding of underlying disease mechanisms. Here, we describe an extended genome-wide association meta-analysis of a well-characterized cohort of 3255 COVID-19 patients with respiratory failure and 12 488 population controls from Italy, Spain, Norway and Germany/Austria, including stratified analyses based on age, sex and disease severity, as well as targeted analyses of chromosome Y haplotypes, the human leukocyte antigen region and the SARS-CoV-2 peptidome. By inversion imputation, we traced a reported association at 17q21.31 to a ~0.9-Mb inversion polymorphism that creates two highly differentiated haplotypes and characterized the potential effects of the inversion in detail. Our data, together with the 5th release of summary statistics from the COVID-19 Host Genetics Initiative including non-Caucasian individuals, also identified a new locus at 19q13.33, including NAPSA, a gene which is expressed primarily in alveolar cells responsible for gas exchange in the lung.S.E.H. and C.A.S. partially supported genotyping through a philanthropic donation. A.F. and D.E. were supported by a grant from the German Federal Ministry of Education and COVID-19 grant Research (BMBF; ID:01KI20197); A.F., D.E. and F.D. were supported by the Deutsche Forschungsgemeinschaft Cluster of Excellence ‘Precision Medicine in Chronic Inflammation’ (EXC2167). D.E. was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the Computational Life Sciences funding concept (CompLS grant 031L0165). D.E., K.B. and S.B. acknowledge the Novo Nordisk Foundation (NNF14CC0001 and NNF17OC0027594). T.L.L., A.T. and O.Ö. were funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project numbers 279645989; 433116033; 437857095. M.W. and H.E. are supported by the German Research Foundation (DFG) through the Research Training Group 1743, ‘Genes, Environment and Inflammation’. L.V. received funding from: Ricerca Finalizzata Ministero della Salute (RF-2016-02364358), Italian Ministry of Health ‘CV PREVITAL’—strategie di prevenzione primaria cardiovascolare primaria nella popolazione italiana; The European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS- and for the project ‘REVEAL’; Fondazione IRCCS Ca’ Granda ‘Ricerca corrente’, Fondazione Sviluppo Ca’ Granda ‘Liver-BIBLE’ (PR-0391), Fondazione IRCCS Ca’ Granda ‘5permille’ ‘COVID-19 Biobank’ (RC100017A). A.B. was supported by a grant from Fondazione Cariplo to Fondazione Tettamanti: ‘Bio-banking of Covid-19 patient samples to support national and international research (Covid-Bank). This research was partly funded by an MIUR grant to the Department of Medical Sciences, under the program ‘Dipartimenti di Eccellenza 2018–2022’. This study makes use of data generated by the GCAT-Genomes for Life. Cohort study of the Genomes of Catalonia, Fundació IGTP (The Institute for Health Science Research Germans Trias i Pujol) IGTP is part of the CERCA Program/Generalitat de Catalunya. GCAT is supported by Acción de Dinamización del ISCIII-MINECO and the Ministry of Health of the Generalitat of Catalunya (ADE 10/00026); the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529). M.M. received research funding from grant PI19/00335 Acción Estratégica en Salud, integrated in the Spanish National RDI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (European Regional Development Fund (FEDER)-Una manera de hacer Europa’). B.C. is supported by national grants PI18/01512. X.F. is supported by the VEIS project (001-P-001647) (co-funded by the European Regional Development Fund (ERDF), ‘A way to build Europe’). Additional data included in this study were obtained in part by the COVICAT Study Group (Cohort Covid de Catalunya) supported by IsGlobal and IGTP, European Institute of Innovation & Technology (EIT), a body of the European Union, COVID-19 Rapid Response activity 73A and SR20-01024 La Caixa Foundation. A.J. and S.M. were supported by the Spanish Ministry of Economy and Competitiveness (grant numbers: PSE-010000-2006-6 and IPT-010000-2010-36). A.J. was also supported by national grant PI17/00019 from the Acción Estratégica en Salud (ISCIII) and the European Regional Development Fund (FEDER). The Basque Biobank, a hospital-related platform that also involves all Osakidetza health centres, the Basque government’s Department of Health and Onkologikoa, is operated by the Basque Foundation for Health Innovation and Research-BIOEF. M.C. received Grants BFU2016-77244-R and PID2019-107836RB-I00 funded by the Agencia Estatal de Investigación (AEI, Spain) and the European Regional Development Fund (FEDER, EU). M.R.G., J.A.H., R.G.D. and D.M.M. are supported by the ‘Spanish Ministry of Economy, Innovation and Competition, the Instituto de Salud Carlos III’ (PI19/01404, PI16/01842, PI19/00589, PI17/00535 and GLD19/00100) and by the Andalussian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018, COVID-Premed, COVID GWAs). The position held by Itziar de Rojas Salarich is funded by grant FI20/00215, PFIS Contratos Predoctorales de Formación en Investigación en Salud. Enrique Calderón’s team is supported by CIBER of Epidemiology and Public Health (CIBERESP), ‘Instituto de Salud Carlos III’. J.C.H. reports grants from Research Council of Norway grant no 312780 during the conduct of the study. E.S. reports grants from Research Council of Norway grant no. 312769. The BioMaterialBank Nord is supported by the German Center for Lung Research (DZL), Airway Research Center North (ARCN). The BioMaterialBank Nord is member of popgen 2.0 network (P2N). P.K. Bergisch Gladbach, Germany and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany. He is supported by the German Federal Ministry of Education and Research (BMBF). O.A.C. is supported by the German Federal Ministry of Research and Education and is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy—CECAD, EXC 2030–390661388. The COMRI cohort is funded by Technical University of Munich, Munich, Germany. This work was supported by grants of the Rolf M. Schwiete Stiftung, the Saarland University, BMBF and The States of Saarland and Lower Saxony. K.U.L. is supported by the German Research Foundation (DFG, LU-1944/3-1). Genotyping for the BoSCO study is funded by the Institute of Human Genetics, University Hospital Bonn. F.H. was supported by the Bavarian State Ministry for Science and Arts. Part of the genotyping was supported by a grant to A.R. from the German Federal Ministry of Education and Research (BMBF, grant: 01ED1619A, European Alzheimer DNA BioBank, EADB) within the context of the EU Joint Programme—Neurodegenerative Disease Research (JPND). Additional funding was derived from the German Research Foundation (DFG) grant: RA 1971/6-1 to A.R. P.R. is supported by the DFG (CCGA Sequencing Centre and DFG ExC2167 PMI and by SH state funds for COVID19 research). F.T. is supported by the Clinician Scientist Program of the Deutsche Forschungsgemeinschaft Cluster of Excellence ‘Precision Medicine in Chronic Inflammation’ (EXC2167). C.L. and J.H. are supported by the German Center for Infection Research (DZIF). T.B., M.M.B., O.W. und A.H. are supported by the Stiftung Universitätsmedizin Essen. M.A.-H. was supported by Juan de la Cierva Incorporacion program, grant IJC2018-035131-I funded by MCIN/AEI/10.13039/501100011033. E.C.S. is supported by the Deutsche Forschungsgemeinschaft (DFG; SCHU 2419/2-1).Peer reviewe

Detailed stratified GWAS analysis for severe COVID-19 in four European populations

Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our understanding of underlying disease mechanisms. Here, we describe an extended GWAS meta-analysis of a well-characterized cohort of 3,260 COVID-19 patients with respiratory failure and 12,483 population controls from Italy, Spain, Norway and Germany/Austria, including stratified analyses based on age, sex and disease severity, as well as targeted analyses of chromosome Y haplotypes, the human leukocyte antigen (HLA) region and the SARS-CoV-2 peptidome. By inversion imputation, we traced a reported association at 17q21.31 to a highly pleiotropic ∼0.9-Mb inversion polymorphism and characterized the potential effects of the inversion in detail. Our data, together with the 5th release of summary statistics from the COVID-19 Host Genetics Initiative, also identified a new locus at 19q13.33, including NAPSA, a gene which is expressed primarily in alveolar cells responsible for gas exchange in the lung.Andre Franke and David Ellinghaus were supported by a grant from the German Federal Ministry of Education and Research (01KI20197), Andre Franke, David Ellinghaus and Frauke Degenhardt were supported by the Deutsche Forschungsgemeinschaft Cluster of Excellence “Precision Medicine in Chronic Inflammation” (EXC2167). David Ellinghaus was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the Computational Life Sciences funding concept (CompLS grant 031L0165). David Ellinghaus, Karina Banasik and Søren Brunak acknowledge the Novo Nordisk Foundation (grant NNF14CC0001 and NNF17OC0027594). Tobias L. Lenz, Ana Teles and Onur Özer were funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project numbers 279645989; 433116033; 437857095. Mareike Wendorff and Hesham ElAbd are supported by the German Research Foundation (DFG) through the Research Training Group 1743, "Genes, Environment and Inflammation". This project was supported by a Covid-19 grant from the German Federal Ministry of Education and Research (BMBF; ID: 01KI20197). Luca Valenti received funding from: Ricerca Finalizzata Ministero della Salute RF2016-02364358, Italian Ministry of Health ""CV PREVITAL – strategie di prevenzione primaria cardiovascolare primaria nella popolazione italiana; The European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS- and for the project ""REVEAL""; Fondazione IRCCS Ca' Granda ""Ricerca corrente"", Fondazione Sviluppo Ca' Granda ""Liver-BIBLE"" (PR-0391), Fondazione IRCCS Ca' Granda ""5permille"" ""COVID-19 Biobank"" (RC100017A). Andrea Biondi was supported by the grant from Fondazione Cariplo to Fondazione Tettamanti: "Biobanking of Covid-19 patient samples to support national and international research (Covid-Bank). This research was partly funded by a MIUR grant to the Department of Medical Sciences, under the program "Dipartimenti di Eccellenza 2018–2022". This study makes use of data generated by the GCAT-Genomes for Life. Cohort study of the Genomes of Catalonia, Fundació IGTP. IGTP is part of the CERCA Program / Generalitat de Catalunya. GCAT is supported by Acción de Dinamización del ISCIIIMINECO and the Ministry of Health of the Generalitat of Catalunya (ADE 10/00026); the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529). Marta Marquié received research funding from ant PI19/00335 Acción Estratégica en Salud, integrated in the Spanish National RDI Plan and financed by ISCIIISubdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER-Una manera de hacer Europa").Beatriz Cortes is supported by national grants PI18/01512. Xavier Farre is supported by VEIS project (001-P-001647) (cofunded by European Regional Development Fund (ERDF), “A way to build Europe”). Additional data included in this study was obtained in part by the COVICAT Study Group (Cohort Covid de Catalunya) supported by IsGlobal and IGTP, EIT COVID-19 Rapid Response activity 73A and SR20-01024 La Caixa Foundation. Antonio Julià and Sara Marsal were supported by the Spanish Ministry of Economy and Competitiveness (grant numbers: PSE-010000-2006-6 and IPT-010000-2010-36). Antonio Julià was also supported the by national grant PI17/00019 from the Acción Estratégica en Salud (ISCIII) and the FEDER. The Basque Biobank is a hospitalrelated platform that also involves all Osakidetza health centres, the Basque government's Department of Health and Onkologikoa, is operated by the Basque Foundation for Health Innovation and Research-BIOEF. Mario Cáceres received Grants BFU2016-77244-R and PID2019-107836RB-I00 funded by the Agencia Estatal de Investigación (AEI, Spain) and the European Regional Development Fund (FEDER, EU). Manuel Romero Gómez, Javier Ampuero Herrojo, Rocío Gallego Durán and Douglas Maya Miles are supported by the “Spanish Ministry of Economy, Innovation and Competition, the Instituto de Salud Carlos III” (PI19/01404, PI16/01842, PI19/00589, PI17/00535 and GLD19/00100), and by the Andalussian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018, COVID-Premed, COVID GWAs). The position held by Itziar de Rojas Salarich is funded by grant FI20/00215, PFIS Contratos Predoctorales de Formación en Investigación en Salud. Enrique Calderón's team is supported by CIBER of Epidemiology and Public Health (CIBERESP), "Instituto de Salud Carlos III". Jan Cato Holter reports grants from Research Council of Norway grant no 312780 during the conduct of the study. Dr. Solligård: reports grants from Research Council of Norway grant no 312769. The BioMaterialBank Nord is supported by the German Center for Lung Research (DZL), Airway Research Center North (ARCN). The BioMaterialBank Nord is member of popgen 2.0 network (P2N). Philipp Koehler has received non-financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany. He is supported by the German Federal Ministry of Education and Research (BMBF).Oliver A. Cornely is supported by the German Federal Ministry of Research and Education and is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy – CECAD, EXC 2030 – 390661388. The COMRI cohort is funded by Technical University of Munich, Munich, Germany. Genotyping was performed by the Genotyping laboratory of Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki. This work was supported by grants of the Rolf M. Schwiete Stiftung, the Saarland University, BMBF and The States of Saarland and Lower Saxony. Kerstin U. Ludwig is supported by the German Research Foundation (DFG, LU-1944/3-1). Genotyping for the BoSCO study is funded by the Institute of Human Genetics, University Hospital Bonn. Frank Hanses was supported by the Bavarian State Ministry for Science and Arts. Part of the genotyping was supported by a grant to Alfredo Ramirez from the German Federal Ministry of Education and Research (BMBF, grant: 01ED1619A, European Alzheimer DNA BioBank, EADB) within the context of the EU Joint Programme – Neurodegenerative Disease Research (JPND). Additional funding was derived from the German Research Foundation (DFG) grant: RA 1971/6-1 to Alfredo Ramirez. Philip Rosenstiel is supported by the DFG (CCGA Sequencing Centre and DFG ExC2167 PMI and by SH state funds for COVID19 research). Florian Tran is supported by the Clinician Scientist Program of the Deutsche Forschungsgemeinschaft Cluster of Excellence “Precision Medicine in Chronic Inflammation” (EXC2167). Christoph Lange and Jan Heyckendorf are supported by the German Center for Infection Research (DZIF). Thorsen Brenner, Marc M Berger, Oliver Witzke und Anke Hinney are supported by the Stiftung Universitätsmedizin Essen. Marialbert Acosta-Herrera was supported by Juan de la Cierva Incorporacion program, grant IJC2018-035131-I funded by MCIN/AEI/10.13039/501100011033. Eva C Schulte is supported by the Deutsche Forschungsgemeinschaft (DFG; SCHU 2419/2-1).N

Application of catalytic hydrodehalogenation for water treatment

Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Química Física Aplicada. Fecha de Lectura: 11-06-2021Esta tesis tiene embargado el acceso al texto completo hasta el 11-12-2022La realización de este trabajo ha sido posible gracias al apoyo económico del Ministerio de Economía y Competitividad (MINECO) a través de los proyectos (CTM2016-76454-R y PID2019-105079-RB-I00) y, de la Comunidad de Madrid (P2018/EMT-4341

In-situ regeneration of a novel Fe3O4/GAC adsorbent for micropollutants removal in a continuous fixed-bed

Adsorption onto activated carbon is one of the most feasible techniques for micropollutants removal from water. Nevertheless, the sustainability and economy of this process is strongly limited by the difficult regeneration of the saturated adsorbents, which, in practice, are commonly disposed. This work aims to tackle this challenge by the development of a granular activated carbon (GAC) decorated with magnetite nanoparticles (Fe3O4/GAC), that allows the in-situ regeneration of the saturated solid by H2O2 addition (through heterogeneous Fenton oxidation). Its performance was tested in a fixed-bed column in continuous operation using the pharmaceutical diclofenac (DCF) as target pollutant. The adsorbent was synthesized by the incorporation of 5% wt. iron to commercial granular activated carbon (GAC) by incipient wetness impregnation, followed by calcination and reduction. The immobilization of magnetite nanoparticles did not significantly alter neither the specific surface area (∼1000 m2 g−1) nor the main properties of the solid, which was fully characterized. Accordingly, its adsorption capacity remained practically unchanged (∼400 mg g−1). Remarkably, the addition of H2O2 allowed to restore the adsorption capacity of the adsorbent at 25 ºC using a H2O2 dose of 3 - 6 g L−1 during 20 h. In-situ regeneration was demonstrated in three consecutive adsorption-regeneration runs for the treatment of 100 mg L−1 DCF, obtaining similar breakthrough curves. Notably, iron leaching was practically negligible during operation and was below 2% wt. of the solid along the regeneration treatment. As a proof of concept, the feasibility of the system was finally proved in the treatment of a representative concentration of DCF (500 µg L−1). The adsorbent led to the complete removal of the pollutant along 10 days and was effectively regenerated after saturation in just 3 hThis research has been supported by the Spanish MINECO thorough the projects PCI2020–112013 and PID2019–105079RB-I00 and by the CM through the project P2018/EMT-4341. J. Nieto-Sandoval and N. Lopez-Arago thank the Spanish MINECO for the FPI grant (BES-2017-081346) and FPI predoctoral grant (PRE2020–094527), respectively. M. Munoz thanks the Spanish MINECO for the Ramón y Cajal postdoctoral contract (RYC-2016–20648

Precious metal-based catalytic membrane reactors for continuous flow catalytic hydrodechlorination

This work is focused on the development of Catalytic Membrane Reactors (CMRs) comprising precious metals as active phases for a comparative assessment in continuous-flow catalytic hydrodechlorination (HDC). HDC has proved its remarkable potential for application as polishing step in drinking water treatment plants, but studies operating in continuous mode are scarce. Preliminary experiments were conducted in batch operation using Pd/Al2O3, Rh/Al2O3 and Pt/Al2O3 powder catalysts to evaluate the influence of the active phase on the removal of prochloraz (PCZ) (100 μg L−1), a pesticide listed on the EU Watch List (2022/1307), by HDC. PCZ removal was successfully described by a pseudo-first order kinetic equation and reaction pathways were proposed. Among the catalysts tested, Pt-based suffered a significant deactivation, not warranting the elimination of this micropollutant. Pd/Al2O3 exhibited a faster removal of PCZ than Rh/Al2O3, while this catalyst resulted in further hydrogenation of the non-chlorinated reaction product. Accordingly, different CMRs were developed by decorating cylindrical inert porous alumina membranes with Pd, Rh, and a combination of Pd-Rh as active phases (∼1% wt.). All CMRs showed a remarkable stability along 100 h on stream, being Pd/CMR be the most effective, with a pseudo-first order rate constant value of 0.062 min−1. An assessment of the impact of operating conditions (aqueous flow rate, PCZ initial concentration, temperature and H2 flow rate) was conducted using the Pd/CMR, which notably remained stable for 450 h on stream. The versatility of the system was finally demonstrated in tap water, achieving a steady-state PCZ conversion close to 95

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective